The Shotlee Journal
Expert insights on GLP-1 medications, peptide therapy, and evidence-based approaches to weight management.
Loading articles...
Showing 9 / 1146 articles
The rise of GLP-1 medications like Ozempic and Mounjaro has brought significant advancements in weight management and diabetes care. However, as more individuals embrace these therapies, understanding and managing potential side effects becomes crucial for a successful health journey.
The rise of GLP-1 medications for weight loss has brought to light a common side effect: temporary hair thinning. This article delves into why this happens and what you can do about it.
Plus-size model Ashley Graham expresses her disappointment and concern over the increasing popularity of GLP-1 weight loss drugs, viewing it as a setback for body acceptance movements.
The traditional concept of retirement is being redefined as men in midlife increasingly focus on maintaining vitality and appearance, extending their 'hotspan' well into later years.
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.
GLP-1 medications are revolutionizing weight management and diabetes care, but their impact extends far beyond the scale. This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers.
AOD-9604, a fragment of human growth hormone, is being studied for its potential to selectively influence lipid metabolism and energy balance, offering a unique lens into peptide signaling.
Novo Nordisk recently unveiled compelling topline results from the PIONEER TEENS trial, suggesting that oral semaglutide could become the first oral GLP-1 Receptor Agonist (RA) therapy approved for children and adolescents managing Type 2 Diabetes (T2D). This development addresses a significant gap in pediatric endocrinology, offering a potentially more accessible treatment option.
